Global ovarian cancer market expected to generate revenue of around USD 4.01 billion by end of 2024, growing at a CAGR of around 11.82% between 2018 and 2024. Ovaries are located on each side of the uterus and are a part of the female reproductive system. Ovaries produce ovum and female hormones progesterone and estrogen.
Sarasota, FL -- (SBWIRE) -- 08/23/2018 -- Zion Market Research has published a new report titled "Ovarian Cancer Market by Type (Epithelial Ovarian Tumors, Ovarian Germ Cell Tumors, Ovarian Stromal Tumors, and Primary Peritoneal Carcinoma), by Cancer Stage (Stage I, Stage II, Stage III, and Stage IV), by Diagnostics (Physical Examination, Biopsy, Blood Tests, Human Chorionic Gonadotropin (hCG) test, ultrasound, MRI, PET, and CT scans), and by Treatment (Chemotherapy, Targeted Therapy, Radiation Therapy, Immunotherapy, Hormonal Therapy, and Surgery): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017 - 2024". According to the report, global ovarian cancer market was valued at approximately USD 1.83 billion in 2017 and is expected to generate revenue of around USD 4.01 billion by end of 2024, growing at a CAGR of around 11.82% between 2018 and 2024.
Request Free Sample Report @ https://www.zionmarketresearch.com/sample/ovarian-cancer-market
Ovaries are located on each side of the uterus and are a part of the female reproductive system. Ovaries produce ovum and female hormones progesterone and estrogen. These female hormones manage the menstrual cycle along with influencing the development of female body characteristics.
There are four major types of ovarian cancer: Epithelial ovarian cancer, Borderline tumors, Germ cell ovarian cancer, and Sex-cord stromal cell cancer. The cancer types are determined based on the location of the ovarian cells where the cancerous growth starts. After starting from ovaries, ovarian cancer spreads to the pelvis and abdomen region. Ovarian cancer is virtually undetectable when it is in the ovaries.
The strongest risk factors that can cause ovarian cancer are acquired genetic changes, genetic mutations called BRCA1 or BRCA2, old age, obesity, not having a full-term pregnancy, using fertility treatment, hormone therapy post menopause, and PTEN tumor hamartoma syndrome.
Factors such as increasing geriatric population of women rise in ovarian cancer cases, availability of new drugs and therapies, increase in healthcare expenditure, and increased government funding are expected to boost the growth of ovarian cancer market. However, availability of generic drugs and patent expiration of branded drugs can act as a restraint in the growth of the ovarian cancer market. The lack of precise diagnostic techniques for ovarian cancer in the early stages can also have a negative impact on the global ovarian cancer market.
Inquiry more about this report @ https://www.zionmarketresearch.com/inquiry/ovarian-cancer-market
On the basis of type, the ovarian cancer market has been divided into epithelial ovarian tumors, ovarian germ cell tumors, ovarian stromal tumors, and primary peritoneal carcinoma. On the basis of the cancer stage, the market is segmented into Stage I, Stage II, Stage III, and Stage IV. On the basis of diagnostics, the market divided into the physical examination, biopsy, blood tests, Human Chorionic Gonadotropin (hCG) test, ultrasound, MRI (Magnetic resonance imaging), PET (Positron emission tomography), and CT scans. On the basis of treatment, the market is divided into chemotherapy, targeted therapy, radiation therapy, immunotherapy, hormonal therapy, and surgery. In the forecast period, the diagnostic segment will dominate the global market as ovarian cancer is most chemosensitive cancer.
North America, Asia Pacific, Europe, the Middle East & Africa, and Latin America are key regional segments of the global ovarian cancer market. North America is anticipated to remain the leading region over the forecast period followed by Europe. Demand for ovarian cancer products and treatments was highest in North America especially in the U.S. Asia Pacific is expected to be the highest growing region in the ovarian cancer market during the forecast period. Moreover, the Middle East & Africa and Latin America are also expected to show moderate growth for this market in the years to come.
Browse the full "Ovarian Cancer Market" report at https://www.zionmarketresearch.com/report/ovarian-cancer-market
Some of the key players in ovarian cancer market include Astra Zeneca Plc, Bristol Myers Squibb Company, Genentech Inc., Eli Lilly and Company, Novogen, Inc., GlaxoSmithKline Plc, Janssen Pharmaceuticals, Inc., Aetera Zenteris Inc., Boehringer Ingelheim GmbH, F. Hoffman-La Roche Ltd., and others.